The prevalence of dyslipidemia by new guidelines NCEP-ATP III in Korean type 2 diabetic patients

被引：0
|
作者：
Kim, DK
Park, MK
Kang, DY
Lee, HJ
机构：
来源：
DIABETES | 2002年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2035
引用
收藏
页码：A495 / A495
页数：1
相关论文
共 50 条
  • [1] METABOLIC SYNDROME: PREVALENCE (IDF & NCEP-ATP III) IN UDHAMPUR, JAMMU CITY
    Sharma, Radhika
    Sharma, Ragini
    Kumar, Anil
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2019, 10 (03): : 1420 - 1425
  • [2] Prediction of type 2 diabetes by NCEP-ATP III and IDF criteria for the metabolic syndrome
    Ludvik, Bernhard
    Obermayr, Rudolf
    Gutjahr, Georg
    Temml, Christian
    DIABETES, 2008, 57 : A668 - A668
  • [3] NCEP-ATP III and IDF criteria for metabolic syndrome predict type 2 diabetes mellitus
    Sulistiowati, Eva
    Sihombing, Marice
    UNIVERSA MEDICINA, 2016, 35 (01) : 46 - 55
  • [4] Stroke patients have cholesterol level's greater than recommended by NCEP-ATP III guidelines
    不详
    FUTURE LIPIDOLOGY, 2007, 2 (02): : 124 - 124
  • [5] Prevalence of metabolic syndrome in Nepalese type 2 diabetic patients according to WHO, NCEP ATP III, IDF and Harmonized criteria
    Pokharel D.R.
    Khadka D.
    Sigdel M.
    Yadav N.K.
    Acharya S.
    Kafle R.C.
    Shukla P.S.
    Journal of Diabetes & Metabolic Disorders, 13 (1):
  • [6] Evaluation of the hypercholesterolemia care cascade and compliance with NCEP-ATP III guidelines in Iran based on the WHO STEPS survey
    Djalalinia, Shirin
    Khosravi, Sepehr
    Yoosefi, Moein
    Salahi, Sarvenaz
    Varniab, Zahra Shokri
    Golestani, Ali
    Rezaei, Nazila
    Kazemi, Ameneh
    Dilmaghani-Marand, Arezou
    Rezaei, Negar
    Ghasemi, Erfan
    Ahmadi, Naser
    Rashidi, Mohammad-Mahdi
    Farzi, Yosef
    Rezaee, Kamyar
    Nasserinejad, Maryam
    Azadnajafabad, Sina
    Abdolhamidi, Elham
    Haghshenas, Rosa
    Derouei, Arefeh Alipour
    Rankohi, Azadeh Momen Nia
    Farzadfar, Farshad
    LIPIDS IN HEALTH AND DISEASE, 2025, 24 (01)
  • [7] Metabolic syndrome in newly diagnosed type 2 diabetes mellitus using NCEP-ATP III, the Nnewi experience
    Osuji, C. U.
    Nzerem, B. A.
    Dioka, C. E.
    Onwubuya, E. I.
    NIGERIAN JOURNAL OF CLINICAL PRACTICE, 2012, 15 (04) : 475 - 480
  • [8] The NCEP-ATP III recommendations result in undertreatment of the lipid abnormalities of patients with impaired fasting glucose
    Aguilar-Salinas, CA
    Rojas, R
    Gomez-Perez, FJ
    Franco, A
    Riostorres, JM
    Valles, V
    Olaiz, G
    Rull, JA
    DIABETES, 2002, 51 : A150 - A150
  • [9] Frequency of Metabolic Syndrome among Hemodialysis Patients According to NCEP-ATP III and IDF Definitions
    Ucar, Edip
    Huzmeli, Can
    Guven, Oguz
    Savas, Nazan
    Gullu, Murat
    Asilyoruk, Sema
    Kuvandik, Ceren
    Temizkan, Aysegul
    Kuvandik, Guven
    RENAL FAILURE, 2009, 31 (03) : 221 - 228
  • [10] Clinical impact of modified NCEP-ATP III criteria on carotid atherosclerosis in Japanese adults including type 2 diabetes
    Teramura, M
    Emoto, M
    Yokoyama, H
    Araki, T
    Mori, K
    Morioka, T
    Koyama, H
    Syoji, T
    Okuno, Y
    Nishizawa, Y
    DIABETES, 2005, 54 : A163 - A163
12345